Clinical Trial Search

Primary: Sensitivity and Specificity of ASPIRE to Detect Malarial Retinopathy in Eyes of the Subjects Clinically Diagnosed With CM — 87; 85 Percentage of participants

Primary: Objective Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 Per Investigator Assessment — 20.0; 13.9 Percent of participants

Primary: Change in Immunologic Markers Following Combination of Study Drug With Chemoradiation — 31.31; 140.33 ratio of cells per mm^2", "CD8+: FoxP3+

Primary: Cold Temperature Deflection Point — 22.8; 22.97 degrees Celsius

Primary: Cohort 1 and 2: Time to Baseline Monthly Seizure Count up to the End of the 12-week Double-blind (DB) Treatment Period — 32; 34; 29; 38 Days — p=0.3571

Primary: Acceptability of Workbook Assessed Through Likert Score Scale — 10; 3 Participants

Primary: Change From Baseline in Oxygen Consumption During Maximal Bike Exercise — 14.45; 14.18 mL/kg/min — p=0.823

Primary: Primary Safety Endpoint: Serious Adverse Event Rate — 0; 2.7 percentage of patients

Primary: Cumulative Incidence (Estimated Percentage of Participants) Who Developed Toxicities Following Radiation Treatment — 17.7 percentage of participants

Primary: Dose Conversion Factor — 4.24 Ratio

Primary: Number of Participants Who Continue Study Participation at 12 Weeks — 26; 29 Participants

Primary: Number of HIV Care Visits — 1.00; 3.00 HIV Care Visits

Primary: Lens Fit Acceptance Ratings — 3.3; 3.7 Units on Scale

Primary: Count of Self-Report of Advance Directive — 10; 5; 67; 6 Participants

Primary: Change in MMD (Monthly Migraine Days) — -3.04; -2.14 migraine days per month